5-Chlorodeoxycytidine, a radiosensitizer effective against RIF-1 and lewis lung carcinoma, is also effective against a DMBA-induced mammary adenocarcinoma and the EMT-6 tumor in BALB/c mice

Sheldon Greer, Orlando Santos, Charles Gottlieb, James Schwade, H. Stan Marion

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

5-Chlorodeoxycytidine (CldC), coadministered with modulators of pyrimidine metabolism, is an effective radiosensitizer of murine tumors. Past studies that utilized RIF-1 tumors in C3H mice and Lewis lung carcinoma (LLC) in BDF1 mice have been extended with an emphasis on using multiple cycles of drug administration followed by irradiation of LLC and the use of two additional tumor models. Four of seven cures of BDF1 mice bearing LLC were obtained with three doses of 20 Gy irradiation, in which the first and third dose were preceded by a "Standard Protocol" that includes N-(phosphonacetyl)-L-asparatic acid (PALA), 5-fluorodeoxycytidine (FdC), tetrahydrouridine, and the radiosensitizer, 5-chlorodeoxycytidine. No cures were obtained in groups of mice receiving radiation alone or drugs alone, and there were no "no takes" in untreated control groups (six mice/group). Extensive tumor inhibition, exceeding that obtained with drugs or radiation alone, was obtained with two cycles of drugs and radiation combined when a dimethybenzanthracene-induced mammary adenocarcinoma was used in BALB/c mice. With the EMT-6 tumor in BALB/c mice, doses of 10 and 20 Gy were administered 9 and 16 days after tumor implantation, each preceded with the Standard Protocol; this resulted in a tumor growth delay of 24 days. No tumor growth delay occurred with drugs or radiation alone. The omission of PALA, FdC or CIdC from the Standard Protocol resulted in loss of tumor control, which was obtained with the complete protocol. The fact that 5-chlorodeoxycytidine is an effective radiosensitizer in four rodent tumor systems is compelling evidence that it has potential as a radiosensitizer of human tumors, especially in view of its tumor selectivity and its resistance to catabolism when used with modulators of its metabolism, and in view of the high levels of the key enzymes in human tumors, which can convert 5-chlorodeoxycytidine to 5-chlorodeoxyruridine triphosphate, the proximate radiosensitizer.

Original languageEnglish
Pages (from-to)505-510
Number of pages6
JournalInternational journal of radiation oncology, biology, physics
Volume22
Issue number3
DOIs
StatePublished - Jan 1 1992
Externally publishedYes

Fingerprint

Lewis Lung Carcinoma
9,10-Dimethyl-1,2-benzanthracene
lungs
mice
Adenocarcinoma
Breast
tumors
cancer
Neoplasms
drugs
Radiation
Pharmaceutical Preparations
metabolism
radiation
5-chloro-2'-deoxycytidine
dosage
Tetrahydrouridine
modulators
catabolism
rodents

Keywords

  • 5-Chloro-2′-deoxycytidine
  • 5-fluorodeoxycytidine
  • EMT-6 tumor
  • Lewis lung carcinoma
  • N-(phosphonacetyl)-L-aspartic acid (PALA)
  • Tetrahydrouridine

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

5-Chlorodeoxycytidine, a radiosensitizer effective against RIF-1 and lewis lung carcinoma, is also effective against a DMBA-induced mammary adenocarcinoma and the EMT-6 tumor in BALB/c mice. / Greer, Sheldon; Santos, Orlando; Gottlieb, Charles; Schwade, James; Stan Marion, H.

In: International journal of radiation oncology, biology, physics, Vol. 22, No. 3, 01.01.1992, p. 505-510.

Research output: Contribution to journalArticle

@article{08d74bd4387449e493add37b72debd92,
title = "5-Chlorodeoxycytidine, a radiosensitizer effective against RIF-1 and lewis lung carcinoma, is also effective against a DMBA-induced mammary adenocarcinoma and the EMT-6 tumor in BALB/c mice",
abstract = "5-Chlorodeoxycytidine (CldC), coadministered with modulators of pyrimidine metabolism, is an effective radiosensitizer of murine tumors. Past studies that utilized RIF-1 tumors in C3H mice and Lewis lung carcinoma (LLC) in BDF1 mice have been extended with an emphasis on using multiple cycles of drug administration followed by irradiation of LLC and the use of two additional tumor models. Four of seven cures of BDF1 mice bearing LLC were obtained with three doses of 20 Gy irradiation, in which the first and third dose were preceded by a {"}Standard Protocol{"} that includes N-(phosphonacetyl)-L-asparatic acid (PALA), 5-fluorodeoxycytidine (FdC), tetrahydrouridine, and the radiosensitizer, 5-chlorodeoxycytidine. No cures were obtained in groups of mice receiving radiation alone or drugs alone, and there were no {"}no takes{"} in untreated control groups (six mice/group). Extensive tumor inhibition, exceeding that obtained with drugs or radiation alone, was obtained with two cycles of drugs and radiation combined when a dimethybenzanthracene-induced mammary adenocarcinoma was used in BALB/c mice. With the EMT-6 tumor in BALB/c mice, doses of 10 and 20 Gy were administered 9 and 16 days after tumor implantation, each preceded with the Standard Protocol; this resulted in a tumor growth delay of 24 days. No tumor growth delay occurred with drugs or radiation alone. The omission of PALA, FdC or CIdC from the Standard Protocol resulted in loss of tumor control, which was obtained with the complete protocol. The fact that 5-chlorodeoxycytidine is an effective radiosensitizer in four rodent tumor systems is compelling evidence that it has potential as a radiosensitizer of human tumors, especially in view of its tumor selectivity and its resistance to catabolism when used with modulators of its metabolism, and in view of the high levels of the key enzymes in human tumors, which can convert 5-chlorodeoxycytidine to 5-chlorodeoxyruridine triphosphate, the proximate radiosensitizer.",
keywords = "5-Chloro-2′-deoxycytidine, 5-fluorodeoxycytidine, EMT-6 tumor, Lewis lung carcinoma, N-(phosphonacetyl)-L-aspartic acid (PALA), Tetrahydrouridine",
author = "Sheldon Greer and Orlando Santos and Charles Gottlieb and James Schwade and {Stan Marion}, H.",
year = "1992",
month = "1",
day = "1",
doi = "10.1016/0360-3016(92)90863-D",
language = "English",
volume = "22",
pages = "505--510",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - 5-Chlorodeoxycytidine, a radiosensitizer effective against RIF-1 and lewis lung carcinoma, is also effective against a DMBA-induced mammary adenocarcinoma and the EMT-6 tumor in BALB/c mice

AU - Greer, Sheldon

AU - Santos, Orlando

AU - Gottlieb, Charles

AU - Schwade, James

AU - Stan Marion, H.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - 5-Chlorodeoxycytidine (CldC), coadministered with modulators of pyrimidine metabolism, is an effective radiosensitizer of murine tumors. Past studies that utilized RIF-1 tumors in C3H mice and Lewis lung carcinoma (LLC) in BDF1 mice have been extended with an emphasis on using multiple cycles of drug administration followed by irradiation of LLC and the use of two additional tumor models. Four of seven cures of BDF1 mice bearing LLC were obtained with three doses of 20 Gy irradiation, in which the first and third dose were preceded by a "Standard Protocol" that includes N-(phosphonacetyl)-L-asparatic acid (PALA), 5-fluorodeoxycytidine (FdC), tetrahydrouridine, and the radiosensitizer, 5-chlorodeoxycytidine. No cures were obtained in groups of mice receiving radiation alone or drugs alone, and there were no "no takes" in untreated control groups (six mice/group). Extensive tumor inhibition, exceeding that obtained with drugs or radiation alone, was obtained with two cycles of drugs and radiation combined when a dimethybenzanthracene-induced mammary adenocarcinoma was used in BALB/c mice. With the EMT-6 tumor in BALB/c mice, doses of 10 and 20 Gy were administered 9 and 16 days after tumor implantation, each preceded with the Standard Protocol; this resulted in a tumor growth delay of 24 days. No tumor growth delay occurred with drugs or radiation alone. The omission of PALA, FdC or CIdC from the Standard Protocol resulted in loss of tumor control, which was obtained with the complete protocol. The fact that 5-chlorodeoxycytidine is an effective radiosensitizer in four rodent tumor systems is compelling evidence that it has potential as a radiosensitizer of human tumors, especially in view of its tumor selectivity and its resistance to catabolism when used with modulators of its metabolism, and in view of the high levels of the key enzymes in human tumors, which can convert 5-chlorodeoxycytidine to 5-chlorodeoxyruridine triphosphate, the proximate radiosensitizer.

AB - 5-Chlorodeoxycytidine (CldC), coadministered with modulators of pyrimidine metabolism, is an effective radiosensitizer of murine tumors. Past studies that utilized RIF-1 tumors in C3H mice and Lewis lung carcinoma (LLC) in BDF1 mice have been extended with an emphasis on using multiple cycles of drug administration followed by irradiation of LLC and the use of two additional tumor models. Four of seven cures of BDF1 mice bearing LLC were obtained with three doses of 20 Gy irradiation, in which the first and third dose were preceded by a "Standard Protocol" that includes N-(phosphonacetyl)-L-asparatic acid (PALA), 5-fluorodeoxycytidine (FdC), tetrahydrouridine, and the radiosensitizer, 5-chlorodeoxycytidine. No cures were obtained in groups of mice receiving radiation alone or drugs alone, and there were no "no takes" in untreated control groups (six mice/group). Extensive tumor inhibition, exceeding that obtained with drugs or radiation alone, was obtained with two cycles of drugs and radiation combined when a dimethybenzanthracene-induced mammary adenocarcinoma was used in BALB/c mice. With the EMT-6 tumor in BALB/c mice, doses of 10 and 20 Gy were administered 9 and 16 days after tumor implantation, each preceded with the Standard Protocol; this resulted in a tumor growth delay of 24 days. No tumor growth delay occurred with drugs or radiation alone. The omission of PALA, FdC or CIdC from the Standard Protocol resulted in loss of tumor control, which was obtained with the complete protocol. The fact that 5-chlorodeoxycytidine is an effective radiosensitizer in four rodent tumor systems is compelling evidence that it has potential as a radiosensitizer of human tumors, especially in view of its tumor selectivity and its resistance to catabolism when used with modulators of its metabolism, and in view of the high levels of the key enzymes in human tumors, which can convert 5-chlorodeoxycytidine to 5-chlorodeoxyruridine triphosphate, the proximate radiosensitizer.

KW - 5-Chloro-2′-deoxycytidine

KW - 5-fluorodeoxycytidine

KW - EMT-6 tumor

KW - Lewis lung carcinoma

KW - N-(phosphonacetyl)-L-aspartic acid (PALA)

KW - Tetrahydrouridine

UR - http://www.scopus.com/inward/record.url?scp=0026550123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026550123&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(92)90863-D

DO - 10.1016/0360-3016(92)90863-D

M3 - Article

C2 - 1735688

AN - SCOPUS:0026550123

VL - 22

SP - 505

EP - 510

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -